Research Article
The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases
Table 1
Patient demographics and medication treatment.
| | | Total group (%) | Crohn’s (%) | Ulcerative colitis (%) |
| | Total patients | 127 | 82 (65) | (35) | | Male patient | 72 (57) | 49 (60) | 23 (50) | Age at diagnosis in years,
mean (std. Dev.) | 10.38 (4.00) | 11.06 (3.47) | 9.17 (4.54) | | Disease activity at diagnosis PCDAI for CD, PUCAI for UC Mean (std. Dev.) | NA | 21.7 (11.16) | 31.9 (16.56) | | Duration of disease since diagnosis in years: median (IQR) | 3.2 (2 to 5.9) | 3.1 (2.1 to 6.3) | 3.2 (1.9 to 4.7) | | 5ASA therapy | 39 (31) | 10 (12) | 30 (65) | | AZA therapy | 56 (44) | 38 (46) | 18 (39) | | MTX therapy | 29 (23) | 25 (30) | 4 (8.7) | | Infliximab therapy | 42 (33) | 33 (40) | 9 (20) | | Adalimumab | 3 (2.4) | 2 (2.4) | 1 (2.1) |
| | 5ASA monotherapy | 22 (17) | 2 (2.4) | 20 (43) |
| | AZA monotherapy w/o 5ASA | 26 (20) | 24 (29) | 3 (6.5) | | AZA monotherapy w 5ASA | 12 (9.4) | 4 (4.8) | 9 (20) | | AZA monotherapy w or w/o 5ASA | 38 (30) | 27 (33) | 11 (24) |
| | MTX monotherapy w/o 5ASA | 8 (6.7) | 8 (10) | 2 (4.3) | | MTX monotherapy w 5ASA | 2 (1.6) | 2 (2.4) | 0 (0.0) | | MTX monotherapy w or wo 5ASA | 10 (79) | 9 (11) | 2 (4.3) |
| | Infliximab monotherapy | 7 (5.5) | 7 (8.5) | 0 (0.0) | | Infliximab & AZA | 18 (14) | 11 (13) | 7 (15) | | Infliximab & AZA & 5ASA | 4 (3.1) | 2 (2.4) | 3 (6.5) | | Infliximab & MTX | 17 (13) | 15 (18) | 2 (4.3) | | Infliximab & MTX & 5ASA | 2 (1.6) | 1 (1.2) | 1 (2.1) |
| | Adalimumab monotherapy | 1 (0.7) | 0 (0.0) | 1 (2.1) | | Adalimumab & MTX | 2 (1.6) | 2 (2.4) | 0 (0.0) |
|
|
1 subject has IBD-U. No patient on biologics and ASA alone. No patients on Adalimumab and AZA or Adalimumab and ASA alone. |
